SHANGHAI and BOSTON, April 17, 2025 /PRNewswire/ -- VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specific antibodies and antibody-drug conjugate (ADC), today announced its second...
Hence then, the article about velavigo announces second out licensing deal of a first in class bi specific antibody further validating its innovative discovery platform and sustainable bd vc business model was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model )
Also on site :
- Did 'Summer House: The Aftermath' Just Hard Launch Amanda Batula's Redemption Arc? Some Fans Say 'Too Late'
- A Shocking Recoupling! And the Second Vote Opens! Who Are the New Couples of ‘Love Island USA’ 2026
- Musk’s Grok AI helped fire 2,000 missiles at Iran – Pentagon